Could a common heart drug cut COPD hospitalizations?

NCT ID NCT03566667

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial tests whether adding the beta-blocker metoprolol to standard care can reduce a combined risk of death, COPD flare-ups, and heart-related hospitalizations in people with COPD who do not have known heart disease. About 1,700 adults with COPD will receive either metoprolol or usual care, and their outcomes will be tracked for one year. The goal is to see if this inexpensive drug can offer broader protection for COPD patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Metoprolol, a beta-blocker, added to standard COPD care
What this could lead to
If it works, this could offer a low-cost way to reduce hospitalizations and deaths in people with COPD, even without heart disease.
What could go wrong
This is a pragmatic, unblinded trial, so results may be influenced by expectations. Metoprolol can cause side effects like low blood pressure or fatigue, and may not benefit all COPD patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Hospital of Örebro

    Örebro, 701 85, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.